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Abstract
Expression profiling by DNA microarray analysis
has provided insights into molecular alterations that
underpin cancer progression andmetastasis. Although
differential expression of microarray-defined probes
can be related to numerical or structural chromosomal
alterations, it is unclear if such changes are also clus-
tered in distinct chromosomes or genomic regions
and whether chromosomal alterations always reflect
changes in gene expression. Here we apply the dChip
algorithm and a novel technique to test the hypothe-
sis that expression changes occurring as a function of
tumor progression and metastasis are nonrandomly
distributed. Expression profiling of a human xenograft
model of lungmetastasis phenotype indicates that chro-
mosomes 2, 11, and 20 contain higher percentages of
differentially expressedgenes (P < .05). Furthermore,we
show that a number of differentially expressed probes
mapped to chromosome 17q, defining the existence of
an expression ‘‘hot spot’’ corresponding to an area of
gain determined by comparative genomic hybridization
(CGH). Interestingly, other areas of gains detected by
CGH were not associated with expression hot spots.
In summary, we show that gene expression changes
during bladder cancer lung metastasis occur non-
randomly in specific chromosomes and intrachromo-
somal locations.
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Introduction
The use of DNA microarrays has revolutionized the mea-
surement of gene expression in human cancer by providing
insights into genes involved in tumorigenesis and metasta-
sis [1], into the discovery of potential tumor biomarkers
[2,3], and into the molecular classification of common neo-
plasms [4]. Some differentially expressed genes have been
associated with specific chromosomal gains and losses, as
determined by karyotyping and comparative genomic hybrid-
ization (CGH) [5,6], whereas others appear not to be due to
structural chromosomal alterations. Thus far, no evaluation
has yet been performed to determine whether such gene ex-
pression changes occur either in specific chromosomes or in
distinct chromosomal regions (‘‘hot spots’’) during bladder
tumor metastasis.
In the current study, we use both an established and a novel
bioinformatics approach to the discovery and mapping of gene
expression hot spots. We apply these approaches to gene
expression profiling data obtained from a newly described
model of lung metastasis in progressive bladder cancer [7],
and we use this model to determine if genes whose expression
is altered as a function of increasing metastatic potential are
randomly distributed or clustered in specific chromosomes or
chromosomal regions. In addition, we evaluate the bladder cell
lines in this model for genomic alterations to see whether such
alterations are associated with gene expression hot spots.
Materials and Methods
Xenograft Model of Lung Metastasis in Progressive
Bladder Cancer
The xenograft model of lung metastasis in progressive
bladder cancer was recently described [7]. In this model, a
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sequential series of cell lines was generated from a set of
more progressive metastatic tumors selected in vivo. To
accomplish this, T24T cells [8], which are tumorigenic and
poorly metastatic variants of T24, were serially passaged
in nude mice. The derivative cell lines with increasing pul-
monary metastatic ability were named FL1, FL2, and FL3
(Figure 1). Gene expression analysis of T24T, FL1, FL2, and
FL3 was performed as previously described using the HG-
U133A GeneChip array (Affymetrix, Santa Clara, CA). Up-
regulated and downregulated genes were identified as a
function of metastatic ability [7] and were used in the gene
mapping analysis described below.
Karyotypic Analysis
Cultures of the T24T cell line and the sublines FL1, FL2,
and FL3 were initiated by placing aliquots of trypsinized cells
on small glass coverslips. The coverslips were incubated for
4 to 7 days at 37jC in minimum essential medium (Gibco,
Grand Island, NY) supplemented with 20% fetal bovine
serum and penicillin/streptomycin (Gibco). When adequate
mitotic cells had been observed, the coverslips were treated
with Colcemid (Gibco) overnight and harvested in situ, accord-
ing to standard methods [9]. The coverslips were stained
using a standard trypsin–Giemsa banding method. Five kar-
yotypes were produced from each cell line. The final karyotype
designation was based on a composite, as indicated by ‘‘cp’’
at the end of the description and following standard ISCN
1995 nomenclature.
CGH
DNA was extracted from the T24T and FL1–FL3 cell
lines, and CGH was performed using a mixture of fluoro-
chromes conjugated to dCTP and dUTP nucleotides for nick
translation [10]. Hybridization, washing, and ISIS digital
image analysis (Metasystems GmbH, Altlussheim, Ger-
many) were performed as described [11]. All CGH results
were confirmed using a 99% confidence interval. Briefly,
intraexperiment standard deviations for all positions in CGH
ratio profiles were calculated from the variation of ratio
values of all homologous chromosomes within the experi-
ment. Confidence intervals for the ratio profiles were then
computed by combining them with an empirical interex-
periment standard deviation and by estimating error proba-
bilities based on t distribution. For the analysis of the
frequencies of DNA copy number changes, we accepted
only changes seen using fixed cutoff values and confirmed
with 99% confidence.
Controls
In each CGH experiment, a negative control (peripheral
blood DNA from a healthy donor) and a positive control were
included. The positive control was a gastric tumor with
known DNA copy number changes. Based on our earlier re-
ports and on control results, we used 1.17 and 0.85 as cutoff
levels for gains and losses, respectively. High-level amplifi-
cation (HLA) was considered at z1.50.
Chromosome Mapping of Genes Differentially Expressed
in Association with Tumor Progression
For the discovery of hot spots, we applied two different
techniques. The first is the ‘‘Genome View’’ algorithm from
dChip, a popular program used in the analysis of gene
expression data (http://www.dchip.org/). The second is a
novel method developed for this manuscript based on a
Figure 1. Diagram of model and analysis. A diagram of cell lines with increasing lung metastatic ability in a bladder cancer model. Microarray analysis is performed
to profile probe expression changes in association with lung metastasis. Differentially expressed probes are applied to probe expression chromosome mapping
analyses. These results are then compared to those obtained on the same xenograft model using Comparative Genomic Hybridization.
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comparison of locations of differentially expressed genes with
that of locations of all spotted probes. In addition, to detect
whether a particular chromosome had a high percentage of
mapped genes that are significantly differentially expressed in
association with tumor progression, we used a logistic regres-
sion in which the outcome was defined as whether or not a
gene was significant. Because three chromosomes had no
genes that were differentially expressed in the xenograft
model, we added 0.5 to all cell counts. To discover if specific
chromosomal regions contain differentially expressed genes
at higher densities (physically concentrated; i.e., hot spots),
the data were modeled as a nonstationary Poisson process.
The model was implemented by applying a software typically
used for counting process survival analysis [12,13]. Because
the genes represented by probe sets in the microarray were
unevenly distributed in the genome, it was necessary to
account for the frequency of differentially expressed genes
relative to the entire probe set distribution. Therefore, consid-
ering physical basepair distance as the metameter in sur-
vival analysis, derivation of the baseline survival curve using
all probe sets for each chromosome comprised the control
group. Evaluation of the hazard rate of differentially ex-
pressed genes in a similar fashion constituted the experi-
mental group. In this setting, the test for proportional hazards
assumption of the Cox model [14] detects whether the ‘‘haz-
ard’’ of genes being differentially expressed (in the experimen-
tal group) is proportional to the hazard of genes being probed
(in the control group). Thus, this approach analyzes whether
there is any statistically meaningful unevenness in the dis-
tribution of differentially expressed genes in a chromosome
once the distribution of probed genes has been taken into
account. Because the test of proportional hazards simulta-
neously considers all the genes of a chromosome when
comparing the significant ones with the baseline, there would
be only one test performed; hence, no multiple-comparison
issue arises. For figure generation and plots, differential ex-
pression data and annotations were exported from Affymetrix
MAS 5.0 software and converted to text files. Custom scripts
were written in Perl and R programming languages to render
expression levels against chromosome positions. The Na-
tional Center for Biotechnology Information data were used
for chromosome lengths. The code for chromosome render-
ing was based on the Colored Chromosomes project [15].
Results
Gene Expression Mapping of Metastatic Phenotype
in a Xenograft Model
We have previously described a bladder cancer metas-
tasis model that represents a series of cell lines with progres-
sively increased metastatic potential [7]. Genes whose
altered expression was associated with metastatic pro-
gression were identified using high-density oligonucleotide
microarrays containing f22,500 probe sets. Of 18,513
evaluable probe sets, 164 were found to be significantly
differentially expressed in association with lung metastasis.
Sixteen of these probe sets did not have a chromosomal
position assignment, which precluded their further analysis.
An overview of gene expression mapping analysis and CGH
is shown in Figure 1.
To detect whether a particular chromosome had a high
percentage of mapped genes significantly differentially ex-
pressed with increasing lung metastasis, we used logistic re-
gression in which the outcome was defined as whether
or not a gene was significant. Overall, 0.8% of genes was
found to be significant (Figure 2A). Chromosomes 2, 11, and
20 contained high percentages of differentially expressed
genes (1.4%, 1.5%, and 2.0%, respectively; P < .05), in as-
sociation with increasing lung metastasis, compared to
the overall average. Results of counting process analysis
(Table 1) confirmed that significant genes in chromosomes 2,
11, and 20 were distributed among the chromosomes in
accordance with the baseline density of probed genes;
hence, they had random physical distribution.
A gene (probe) is declared significantly differentially ex-
pressed once its expression is changed in all the three FL
series in the same direction (i.e., up or down), compared to
that of the T24T cell line. The significant proportion of genes
was computed using both upregulated and downregulated
genes, according to the above criteria. In particular, for
chromosome 2, there were 2 downregulated and 15 upregu-
lated significant genes; for chromosome, 11 there were 3
downregulated and 13 upregulated significant genes; and,
for chromosome 20, there were 5 downregulated and 6 up-
regulated significant genes. However, P values for chro-
mosomes 11 and 2 were dependent on the choice of the
count added to cells (to alleviate zero counts). The significant
proportions of genes in chromosomes 2 and 11 are closer to
the overall average proportion across all the chromosomes,
compared to the proportion of chromosome 20. When we
added different values (such as 0.5) to cell counts to remedy
zero cell counts, the proportions for chromosomes 2 and
11 fluctuated around the overall average, with P values fluc-
tuating around the cutoff of 0.05. However, P values for the
proportion of chromosome 20 remained stable. Hence, in a
more conservative approach, we may declare only chro-
mosome 20 to have a significantly higher percentage of
significant genes.
A second analysis was performed to determine if any
differentially expressed genes were clustered in specific
regions in the chromosomes, thus constituting a hot spot—
a chromosomal region with a high density of gene expression
changes as a function ofmetastasis. One such region in chro-
mosome 17qwas identified, even though chromosome 17 did
not contain the largest number of differentially expressed
genes associated with metastatic progression (Table 1).
On examination of the physical distribution of differentially
expressed genes, eight were found to be unique genes
(Table 2) clustered near the end of the long arm (17q21–
17q25) (Figure 2B). Importantly, all but one of these genes,
junction plakoglobin, were upregulated in association with
metastatic progression. Repeating the hot-spot analysis
using dChip provided a greater number of regions (Figure 3).
Interestingly, only one area found in both techniques had a
correlation with chromosomal changes by CGH.
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Karyotypic Analysis of Metastatic Cell Lines
To determine whether chromosome-associated changes
in gene expression were due to overt genetic alterations, we
performed cytogenetic studies of the FL cell series and their
parental cell line T24T. All of the cell lines had complex
karyotypes with multiple structural and numerical abnormali-
ties. The original cell line, T24T, contained between 73 and
80 chromosomes and between 3 and 6 marker chromo-
somes. Consistent abnormalities include: 73–80, (4n±)
XXX, del(X)(q23), del(2)(p12),del(3)(p14), del(4)(q32),
del(8)(p11.2), del(9)(q34), del(9)(p11.2), i(10)(q10),
der(10)t(10;?)(q10;?), 15, der(17)t(17;8)(p11.1;q12),
der(18)t(18;15)(p11.1;q12)(X2), +mar1, +mar2, +mar3,
+mar4[cp5] (Figure 4). These were noted previously, with
some refinements [8]. For example, the der(17)t(17:8)(-
p11.1;q12) identified now was formerly designated as a
marker chromosome.
Compared to T24T, FL1 contained nearly all of the same
numerical and structural abnormalities, with exceptions of
a deletion of the short arm of chromosome 11 and addi-
tional copies of chromosome 22 (between three and five
copies). The karyotypic designation of FL1 was therefore:
73–80, XXX, del(X)(q23), idem (T24T), del(11)(p11.1), +22,
+22. The karyotype of FL2 was identical to that for FL1, but
had an additional copy of chromosome 20 [73–80, XXX,
del(X0(q23), idem (T24T), del(11)(p11.1), +20, +20, +22,
+22]. The karyotype of FL3 was identical to that for FL2, ex-
cept for a deletion of the short arm of chromosome 5 [73–80,
XXX, del(X)(q23), idem (T24T), del(5)(p13), del(11)(p11.1),
+20, +20, +22, +22].
For some chromosomes, there was a correlation between
chromosomal alternations and gene expression. For ex-
ample, chromosomes 11 and 20 had higher-than-average
differentially expressed genes and chromosomal alterations
associated with increasing lung metastasis (deletion of 11p
in all FL series cell lines, but not in T24T; an additional copy
of chromosome 20 was found in FL2 and FL3, but not in FL1
and T24T). For some chromosomes, there was no correla-
tion between karyotypic alterations and differential gene ex-
pression. Additional copy numbers of chromosome 22 in the
FL series versus T24T did not result in detectable differ-
ential gene expression from this chromosome. Although
Figure 2. Expression changes during metastatic progression and chromosomal position. (A) Percent differentially expressed probes during metastatic progression
and chromosomal location. ( – ) Average percent change across all chromosomes.(*) Chromosomes harboring a statistically significantly higher number of
differentially expressed probes with metastatic ability (see text for description). (B) Identification of the high-density area of gene expression changes in
chromosome 17. (i) Chromosome ideogram. (ii) The distribution of all the array probes (black vertical lines) present in the chip, plus the distribution of the
significantly upregulated or downregulated probes in T24T and FL3 tumor progression (red vertical lines). (iii) Graphical representation indicating where
the significant probes are consistently concentrated, taking into account the baseline distribution of the probes. The y-axis represents scaled Schoenfeld residuals.
The two curves are Lowess smoothers with different smoothing parameters fitted to the points. The dashed blue line smoothens more and points to the end of the
chromosome, indicating that the general area of the hot spot is located at the end of the chromosome. The black solid line smoothens less and indicates a few
peaks corresponding to hot spots, the largest of which is near the end of the q arm.
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chromosome 17 harbored a hot spot and chromosome 2 dis-
played a higher-than-average proportion of differentially ex-
pressed genes, both chromosomes did not have additional
genetic changes in associationwith increasing lungmetastasis.
Evaluation of Metastatic Cell Lines by CGH
CGH analyses demonstrated complex DNA changes in all
cell lines (Table 3). The T24T cell line had a total of seven
gains and four losses, and no HLA. FL1–FL3 cell lines had
changes similar to those of T24T. However, these metastatic
lesions were characterized by a progressive accumulation
of additional gains and HLAs in specific chromosomal re-
gions (Table 4). These cumulative genetic changes included
gains at 1q, 3q, 7q, 8q, 9q, 12q, 17q, 18q, and HLA of 20q.
There was no change in the loss profile of DNA copy number
as a function of progression (Table 4).
DNA gains at 17q were detected in all metastatic FL1–
FL3 cells. These gains were associated with our findings
of nine overexpressed probes that mapped to 17q. The mini-
mal common overlapping region using CGH was at 17q12-
qter. The nine overexpressed genes mapped within this
exact area. Although gains of chromosome 20 were seen
in the nonmetastatic cell line (T24T), HLAs of 20q were
characteristic of all metastatic cells. Microarray analysis
indicated an overexpression of four probes that mapped to
20q. These constituted two different genes, transglutaminase
2 (TGM2) and BCL2-like 1 (BCL2L1). Although our results
may be indicative of the role of increased DNA copy numbers
in the overexpression of these genes, other upstream regu-
latory mechanisms cannot be ruled out.
Discussion
Bladder cancer can present either as a superficial lesion
or as a muscularis propria– invasive tumor. Approximately
half of the patients who present with invasive disease
develop metastases despite initial treatment. Because ge-
netic alterations and changes in gene expression are primary
determinants controlling neoplastic transformation and pro-
gression, expression profiling using cDNA microarrays has
been used in human cancers to aid in delineating the mech-
anisms involved in tumor progression [3]. In bladder cancer,
gene expression profiles that are associated with tumor
progression have been defined recently [2,16–18], but no
studies have been conducted to compare gene expression
changes with occurrences of specific genomic abnormalities.
This is important because it is a common assumption that
chromosomal rearrangements and imbalances seen in can-
cer cells affect gene expression, resulting in altered cellular
phenotypes. The correlation between genetic alternations
and gene expression changes has been studied in human
breast tumors, head and neck squamous cell carcinomas,
and gastric adenocarcinomas [6,19,20].
In this study, we used oligonucleotide microarrays to
profile and evaluate gene expression changes in a model of
Table 1. The Distribution of Differentially Expressed Probes and the
Chromosomal Location of Hot Spots in the Xenograft Lung Metastasis Model
of Human Bladder Cancer.
Chromosome Probes Differential Probes* Hot-Spot P Value
1 1,892 12 .8223
2 1,258 17 .6203
3 993 10 .8542
4 694 7 .5973
5 815 9 .9480
6 1,110 9 .7215
7 855 4 .1303
8 644 5 .3682
9 675 5 .0301
10 703 7 .5889
11 1,087 16 .9123
12 1,010 8 .3152
13 342 0 NA
14 632 3 .3525
15 564 3 .2403
16 744 1 .1746
17 1,092 10 .0006
18 273 2 .0514
19 1,092 5 .5896
20 537 11 .4026
21 239 2 .2778
22 500 2 .1293
23 730 0 NA
Y 32 0 NA
Total 18,513 148 –
The hot-spot P value is calculated as described in Materials and Methods
section. The significance level is P < .01.
*The number of significantly differentially expressed probes with consistent
upregulation or downregulation among FL1, FL2, and FL3, when each
compared to T24T, was identified by local pooled error test with a < .05 [41].
Table 2. Ten Probes Representing Eight Genes in the Long Arm of Chromosome 17 with Differential Expression in the Xenograft Lung Metastasis Model of
Human Bladder Cancer.
Probe Set* Gene Name Map Location Fold Differencey P valuez
204990_s_at Integrin, beta 4 17q11-qter 3.3 <.0001
201508_at Insulin-like growth factor binding protein 4 17q12–q21.1 40.7 <.0001
201474_s_at Integrin, alpha 3 17q21.33 2.5 <.0001
201015_s_at Junction plakoglobin 17q21 3.6 <.0001
200923_at Lectin, galactoside-binding, soluble, 3 binding protein 17q25 5.8 <.0001
208657_s_at MLL septin-like fusion 17q25 3.1 <.0001
203167_at Tissue inhibitor of metalloproteinase 2 17q25 2.9 <.0001
41220_at MLL septin-like fusion 17q25 2.1 <.0001
202855_s_at Solute carrier family 16 (monocarboxylic acid transporters), member 3 17q25 1.8 <.0001
202856_s_at Solute carrier family 16 (monocarboxylic acid transporters), member 3 17q25 1.7 <.0001
*Affymetrix (www.Affymetrix.com).
yFold change comparing FL3 with T24T (FL3/T24T).
zP value for local pooled error test (for testing the null hypothesis of equal mean gene expression across T24T, FL1, FL2, and FL3).
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metastatic progression. We identified chromosomes 2, 11,
and 20 as containing a higher percentage of differentially
expressed genes as a function of metastatic progression.
Interestingly, chromosome 20q also showed HLA on CGH
analysis. Amplification of chromosome 20q has been as-
sociated with various cancers, including carcinomas of the
Figure 3. dChip chromosomal clustering analysis of probe expression changes as a function of metastatic competence in the xenograft model. The program dChip
was used to analyze the xenograft model as a function of metastasis. Hot spots were detected at the P = .02 level of significance (http://www.dchip.org), as outlined
in blue boxes. Gray lines indicate probe positions, and black lines indicate probes that were differentially expressed. Observed CGH changes are presented
(Table 4). Changes highlighted in black indicate cases wherein the dChip hot spot is in a location similar to that of the gains found in CGH.
Figure 4. Karyotypes of T24T and FL series. Cell lines were incubated for 5 to 7 days. When adequate mitotic cells had been observed, the coverslips were treated
with Colcemid overnight and harvested in situ, using standard methods. The coverslips were stained using a standard trypsin–Giemsa banding method. Five
karyotypes were produced from each cell line. A representative karyotype of T24T (composite) is shown. T24T has between 73 and 80 chromosomes, with several
consistent structural abnormalities (arrows). The small insert illustrates the deleted chromosomes 2 and 3 that are not seen in this particular cell but are seen in
several others. Larger inset reveals partial karyotypes of the FL1, FL2, and FL3 series, illustrating consistent changes seen compared to those of T24T.
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breast, colon, ovary, andpancreas [21–24]. In addition, a gain
of chromosome 20q has been known to be associated with
genome instability and tumor progression in bladder cancer
[25,26]. Specific genes located in chromosome 20 that are
related to bladder cancer progression includeSTK15 (located
in 20q13), which is associated with chromosomal aneuploidy
[27,28]. Increased expression ofSTK15 has been associated
with bladder tumor grade, invasion, and metastasis [29]. Re-
cently, another gene in chromosome20,CDC91L1, was iden-
tified as an oncogene in bladder cancer and was found to be
amplified and overexpressed in about one third of bladder
cancer cell lines and primary tumors [30]. Finally, the ubiquitin
conjugaseUbcH10, located in 20q13.1, has been reported as
significantly overexpressed in several human tumors, includ-
ing bladder tumors [31].
To determine if there are areas within chromosomes that
harbor unusually high levels of gene expression changes
associated with lung metastasis, we applied a novel bio-
informatics approach for the discovery and mapping of such
gene expression hot spots. We identified chromosome 17q
as harboring such hot spots that are concentrated between
17q12 and 17q22 and near the end of the long arm. This is
consistent with evidence that clusters of functionally related
genes could be located in particular chromosome regions,
and that the expression of genes within a particular location
could be affected by common mechanisms [32,33]. CGH
analysis indicated DNA amplification of this area. Although
alterations in 17q did not appear to correlate with grade,
stage, or vascular invasion [34], losses [35], or gains [5,36],
changes at 17q have been reported in transitional cell carci-
nomas compared to normal bladder tissues. Clustering of
amplified and overexpressed genes at 17q has also been
reported in upper gastrointestinal carcinomas (this study) [6].
Gene expression changes, of course, are not always
associated with structural chromosomal abnormalities. We
did not find a correlation between chromosomal alterations
and gene expression for chromosome 2 despite the fact that
chromosome 2 had a higher-than-average proportion of
significantly differentially expressed genes. A lack of corre-
lation between chromosomal abnormalities and expression
profiles has also been reported by other groups [37,38], sug-
gesting that mechanisms other than structural alterations
influence gene expression in large genomic regions. This
coordinated regional silencing or activation of multiple genes
could be controlled by identified epigenetic changes that
have been described in tumors [39,40].
The dChip software has a discovery tool for hot spots in
gene expression data based on a nonparametric procedure
for testing the uniformity of frequency for all segment regions
of differentially expressed genes. Even though this tool can
sensitively identify many potential locations of hot spots, it
also provides a number of false positives due to multiple
comparisons in a larger number of all segments of differen-
tially expressed genes. To mitigate this pitfall, we have de-
veloped an overall testing procedure based on survival curve
analysis that can rigorously evaluate the existence of hot
spots in each chromosome. These two algorithms attempt
to answer similar questions in that they aim to detect high
(or low) frequencies of differentially expressed genes com-
pared with spotty probe locations. However, they differ in
that: 1) the former (counting process analysis) uses a semi-
parametric estimation of survival curves to evaluate the
overall significance of such survival curve differences,
whereas the latter (dChip) utilizes a nonparametric proce-
dure for testing the uniformity of frequency for all segment
regions of differentially expressed genes; and, consequently,
2) the former performs hypothesis testing on each chromo-
some (24 comparisons), whereas the latter does so for all
consecutive segments within a chromosome (up to a certain
length; e.g., 20 probes) for such a comparison. Therefore, as
noted on the dChip web site, even though the dChip ap-
proach can effectively draw attention to some hot-spot loca-
tions, its P values need to be more carefully considered in
terms of such multiple comparisons. The use of the dChip
algorithm will be quite useful to identify the exact locations
of hot spots after overall test methods, such as ours, have
found statistical significance in certain chromosomes; the
threshold P value of dChip can then be adjusted to re-
duce noise or to increase detection sensitivity compared
to the overall test results. In our current study, by com-
bining dChip and our novel survival curve–based analyses,
Table 4. CGH Changes Observed during Metastatic Progression in the
Xenograft Lung Metastasis Model of Human Bladder Cancer.
Chromosomal Location* T24T FL1 FL2 FL3
1q G G G
3q (3q13.2qter) G G G
7q (7q33qter) G G G
8q (8q24.1qter) G
9q ( 9q21.3q32) G G G
12q (12q23q24.2) G G G
17q (17q12q24) G G G
18q (18q12q22) G G G
20q G HLA HLA HLA
G, gains; HLA, high-level amplification.
*Chromosome arms are shown; the minimal overlapping region is indicated in
parentheses.
Table 3. CGH Changes Observed in the Xenograft Lung Metastasis Model of Human Bladder Cancer.
Cell Line Gains Losses
T24T 1p31.3pter, 2q34q36, 5p13pter, 5q31.3q34, 10q22.1q25.3, 11p12p15.1, 20 4q31.1qter, 8p, 9p13pter, 10p
FL1 1, 2q31q32.1, 3q13.2qter, 5p, 7q33qter, 9q21.3q32, 10q22.1qter, 11p,
12q14qter, 14q24.1q31, 17q12qter, 18q12q22, 20 (20q), 21q
4q31.1qter, 8p, 9p21pter, 10p, 19p
FL2 1, 3q13.2qter, 5p, 5q23.2qter, 7q33qter, 9q21.3q32, 10q22.1qter, 11p,
12q14qter, 17q12qter, 18q12q22, 20 (20q), 21q
4q31.1qter, 8p, 9p21pter, 10p
FL3 1, 3q13.2qter, 5p, 5q23.2qter, 7q33qter, 8q24.1qter, 9q21.3q32,
10q22.1qter, 11p, 12q14qter, 17q12qter, 18q12q22, 20 (20q)
4q31.1qter, 8p, 9p21pter, 10p
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we have reliably determined that the hot-spot location in
17q is associated with metastatic phenotype in human
bladder cancer.
In summary, oligonucleotide microarray analysis was per-
formed to determine differential gene expression in a bladder
cancer cell line metastasis model. Using a novel approach
of chromosomal expression mapping, we found that gene
expression changes with tumor metastasis do not occur
randomly, but instead occur both in specific chromosomes
and in intrachromosomal locations. Because some gene ex-
pression changes among chromosomes do not appear to
be associated with CGH alterations, our data suggest that
the presence of regional chromosomal mechanisms that
control gene expression may be responsible for at least
some of the changes observed during tumor progression.
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